HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.108.055988v1 50/3/376    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mohan, H. K. Articles by Miles, K. A. Search for Related Content PubMed PubMed Citation Articles by Mohan, H. K. Articles by Miles, K. A.

Cost-Effectiveness of ^99mTc-Sestamibi in Predicting Response to Chemotherapy in Patients with Lung Cancer: Systematic Review and Meta-Analysis

¹ Department of Nuclear Medicine, Guys & St. Thomas Hospitals, NHS Trust, London, United Kingdom; and ² Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom

Correspondence: For correspondence or reprints contact: Hosahalli K. Mohan, Department of Nuclear Medicine, Ground Floor, New Guys House, Guys Hospital, St. Thomas St., London SE1 9RT, United Kingdom. E-mail: mohanhk{at}hotmail.com

Multidrug resistance (MDR) is a major problem in lung cancer. ^99mTc-methoxyisobutylisonitrile (^99mTc-MIBI) has been demonstrated to be a noninvasive marker for the diagnosis of MDR-related P glycoprotein and MDR-associated protein expression in various solid tumors. Studies have shown that ^99mTc-MIBI could play a significant role in the management of lung cancer; for example, it could be used in the selection of patients for chemotherapy or radiotherapy or in combined protocols before the start of treatment. Accurate selection of chemosensitive patients with ^99mTc-MIBI would result not only in effective treatment of patients but also in significant cost savings for health care providers. There is increasing pressure on health care providers to consider costs in medical decision making, particularly in the last decade, as several economic evaluations have appeared in the medical literature. The aims of this study were to undertake a systematic review of the performance of ^99mTc-MIBI imaging in the assessment of treatment resistance in lung cancer and to use the findings of the review in a decision tree analysis of the potential cost-effectiveness of ^99mTc-MIBI imaging in selecting lung cancer patients for chemotherapy. Methods: This study included a systematic review of the literature and a meta-analysis together with a cost-effectiveness analysis of studies with a decision tree analysis model. Results: Analysis of the studies revealed that the overall sensitivity of ^99mTc-MIBI in identifying responders to chemotherapy was 94%, the specificity was 90%, and the accuracy was 92%. The sensitivity analysis revealed an incremental cost-effectiveness ratio of greater than £30,000 ($42,900) for the strategy of treating all patients to recover the small loss of life expectancy (7.5 d) associated with the use of ^99mTc-MIBI to preselect patients for chemotherapy. Conclusion: ^99mTc-MIBI SPECT can accurately predict which patients with lung cancer will respond to chemotherapy. The use of ^99mTc-MIBI to preselect patients for chemotherapy has the potential to yield significant cost savings in the health care system without a significant loss of life expectancy for patients.

Key Words: oncology • SPECT • chemotherapy • cost-effectiveness • lung cancer • ^99mTc-MIBI

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]  

This article has been cited by other articles:

				R. Chisin Cost-Effectiveness Analysis J. Nucl. Med., March 1, 2009; 50(3): 338 - 339. [Full Text] [PDF]